Dr. Jeffrey Zweig
“I treat each patient as I would a family member, seeing them as a unique individual, with their own set of goals, wishes, and expectations. Prior to recommending a specific treatment regimen, it is important for me to get to know them, including their background, family and interests, so that together we can form a personalized medical plan implementing the most up-to-date therapies. I believe it is also vital for patients to get to know me, as creating a comfortable patient-physician relationship allows for a strong level of trust and effective bi-directional communication.”
Meet Dr. ZweigJeffrey Zweig, MD was raised in a medical family and grew up in the San Francisco Bay Area. Dr. Zweig received his Bachelor of Arts in Psychology from Emory University in Atlanta, Georgia and earned his Medical Degree from the Sackler School of Medicine, New York State/American Program at Tel Aviv University in Israel. He completed his internship and residency in Internal Medicine at the George Washington University Hospital in Washington, DC, where he also served as chief resident for an additional year. He then went on to complete his fellowship in Hematology and Medical Oncology at Stanford University Hospital and Clinics in Palo Alto, California.
Dr. Zweig is board certified in Internal Medicine, Hematology and Medical Oncology. He specializes in general hematology and oncology with a special interest in treating lung cancer, genitourinary cancers, colorectal cancer, breast cancer, melanoma, lymphoma, leukemia, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome and benign hematology. Dr. Zweig will be seeing patients in Brentwood, Concord and Pleasant Hill.
In his free time, Dr. Zweig enjoys swimming, skiing, cooking, travel, and spending time with his family.
2018 – ABIM Board Certified in Medical Oncology
2018 – ABIM Board Certified in Hematology
2014 – ABIM Board Certified in Internal Medicine
John Muir Medical Center, Walnut Creek
John Muir Medical Center, Concord Campus
San Ramon Regional Medical Center, San Ramon
Sutter Delta Medical Center, Antioch
Dr. Zweig specializes in general hematology and oncology with a special interest in treating lung cancer, genitourinary cancers, colorectal cancer, breast cancer, melanoma, lymphoma, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome and benign hematology.
Kraus S, Lisiansky V, Zweig J, Kapilevich E, Arber N. Chapter 11: Role of Inflammation in Gastrointestinal Diseases. In: Aggarwal B, Krishnan S, and Guha S. Inflammation, Lifestyle, and Chronic Diseases: The Silent Link. Boca Raton, FL: Taylor and Francis Group; 2012:299-326.
Zweig J, Wakelee H. METLung: a disappointing result in a challenging patient population. Transl Cancer Res. 2017;6(Suppl 3):S489-S493. doi:10.21037/tcr.2017.04.02.
Zweig J, Padda SK. Frontline immunotherapy in non-small cell lung cancer. For which patients is platinum passé? American Journal of Hematology/Oncology. 2017;13(7):16-20.
Zweig J, Wakelee H. The evolution of frontline therapy in ALK-positive advanced NSCLC: Which ALK TKI to use upfront? American Journal of Hematology/Oncology. 2017;13(9):32-36.
Zweig J, Wakelee H. The J-ALEX trial – Is frontline alectinib a new standard of care? J Thorac Dis. 2017;9(8):2242-2245. doi:10.21037/jtd.2017.06.134.
Donington JS, Kim YT, Tong B, Moreira AL, Bessich J, Weiss KD, Colson YL, Wigle D, Osarogiagbon RU, Zweig J, Wakelee H, Blasberg J, Daly M, Backhus L, Van Schil P. Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017. J Thorac Onc. 2018;13(6):767-778. doi:10.1016/j.jtho.2018.04.002.
Zweig J, Mancuso M, Jeong Y, et al. Mutations in KEAP1/NRF2 in Metastatic Non-Small Cell Lung Cancer as Predictors of Response to Platinum Chemotherapy. Poster presented at: IASLC 18th Lung Cancer Targeted Therapies Meeting; 2018 Feb 21-24; Santa Monica, CA.
Zweig JR, Neal JW. Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. J Clin Oncol. 2018;36(26):2677-2679. doi:10.1200/JCO.2018.78.8554.
Zweig J, Wakelee H. Chapter 3: Adjuvant and Neoadjuvant Therapy in Non-Small-Cell Lung Cancer. In: Horn L. Pulmonary Adenocarcinoma: Approaches to Treatment. Philadelphia, PA: Elsevier; 2019:35-55.